IQVIA Holdings Inc. IQV
At closeNov 4, 2026, 5:38 AM EST
Pre-market · Nov 4, 5:38 AM ET
- YTD
- +16.49%
- 1 year
- +22.77%
- Market cap
- 43.27B
- Revenue (ttm)
- 17.31B
- Profit margin
- 8.05%
- EPS (ttm)
- 8.22
- Shares out
- 164.80M
- P/E ratio
- 31.95
- Forward P/E
- 18.48
- YTD return
- +16.49%
- 1-year return
- +22.77%
- Volume
- 1.32M
- Avg volume
- 1.41M
- Open
- 255.65
- Previous close
- 258.44
- Day's range
- 252.38 – 263.99
- 52-week range
- 154.50 – 284.50
- Beta
- 1.17
- Analysts
- Strong Buy
- Price target
- 311.89 (+18.8%)
- Earnings date
- Feb 4, 2027
5Y +15.40 (+6.23%)
Key statistics
- Enterprise value
- 56.61B
- PEG ratio
- 0.95
- Price / sales
- 2.50
- Price / book
- 6.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 8.00%
- Free cash flow
- 2.12B
- Total cash
- 2.42B
- Total debt
- 16.31B
- Return on equity
- 21.39%
- Short % of float
- 2.11%
- 50-day average
- 266.06
- 200-day average
- 209.60
Analyst view
Consensus: strong buy
- Target (low)
- 268.00
- Target (mean)
- 311.89
- Target (high)
- 346.00
- Strong buy2
- Buy16
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 3.58.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | 3.60 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | 3.26 | 3.34 | +0.08 | +2.45% |
| Jul 28, 2026 | Jun 30, 2026 | 3.03 | 3.15 | +0.12 | +3.96% |
| May 5, 2026 | Mar 31, 2026 | 2.82 | 2.90 | +0.08 | +2.84% |
| Feb 5, 2026 | Dec 31, 2025 | 3.40 | 3.42 | +0.02 | +0.59% |
| Oct 28, 2025 | Sep 30, 2025 | 2.98 | 3.00 | +0.02 | +0.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | TD Cowen | main | Buy | Buy |
| Oct 28, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 28, 2026 | Truist Securities | main | Buy | Buy |
| Oct 28, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Oct 28, 2026 | Baird | main | Outperform | Outperform |
| Oct 14, 2026 | Stifel | main | Buy | Buy |
About IQVIA Holdings Inc.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- iqvia.com
News
TD Cowen Maintains Buy on IQVIA Holdings, Raises Price Target to $307 
Artisan Global Value Fund Q3 2026 Portfolio Discussion 
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock 
JP Morgan Maintains Overweight on IQVIA Holdings, Raises Price Target to $325 - Truist Securities Maintains Buy on IQVIA Holdings, Raises Price Target to $346
Evercore ISI Group Maintains Outperform on IQVIA Holdings, Raises Price Target to $310 - Baird Maintains Outperform on IQVIA Holdings, Raises Price Target to $328
IQVIA Holdings Inc. $IQV Stock Purchased by Citizens Financial Group Inc. RI 
IQVIA Hldgs Q3 2026 Earnings Call Transcript - IQVIA Holdings Raises FY2026 Adj EPS Guidance from $12.80-$13.00 to $12.90-$13.00 vs $12.96 Est; Raises FY2026 Sales Guidance from $17.275B-$17.475B to $17.350B-$17.500B vs $17.419B Est
Your note
Sign in to keep a note on IQV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOUSBIB ARI B | Chief Executive Officer | Sale | Jul 28, 2026 | 1,379,240 |
| BRUEHLMAN RONALD E | Chief Financial Officer | Stock Award(Grant) | Feb 5, 2026 | 55,996 |
| DANHAKL JOHN G | Director | Stock Award(Grant) | Apr 22, 2026 | 0 |
| FEDOCK MICHAEL J. | Officer | Stock Award(Grant) | Feb 5, 2026 | 9,595 |
| GOGGINS COLLEEN A | Director | Stock Award(Grant) | Apr 22, 2026 | 14,453 |
| GRENFELL ALISTAIR | Officer | Stock Award(Grant) | Feb 5, 2026 | 24,124 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.83% | 14,549,693 | 3.82B | Jun 29, 2026 |
| Harris Associates L.P. | 7.39% | 12,183,830 | 3.20B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.62% | 10,905,053 | 2.86B | Jun 29, 2026 |
| State Street Corporation | 4.56% | 7,508,244 | 1.97B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.55% | 7,501,993 | 1.97B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 3.73% | 6,139,775 | 1.61B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.22% | 5,299,333 | 1.39B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.62% | 4,323,399 | 1.14B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.19% | 3,616,429 | 949.53M | Jun 29, 2026 |
| HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund | 1.58% | 2,605,500 | 684.10M | Jun 29, 2026 |
| HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Fund | 1.56% | 2,565,300 | 673.55M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 2,192,900 | 575.77M | Sep 29, 2026 |